Docetaxel/Vinorelbine Combination Therapy in Non-Small-Cell Lung Cancer

Docetaxel (Taxotere) and vinorelbine (Navelbine) are two of a number of new third-generation chemotherapeutic agents that have become available in recent years. A series of single-agent and combination therapy studies are underway to determine the efficacy of these agents in the treatment of patients with non-small-cell lung cancer. Although docetaxel and vinorelbine are considered tubulin-binding agents, their use in combination therapy is promising because each has different effects on microtubule assembly (Figure 1).[1]